Generalized Anxiety Disorder
Antidepressants may improve treatment response in generalized anxiety disorder vs. placebo
Antidepressants were more effective than placebo in reducing anxiety symptoms among adults with moderate to severe generalized anxiety disorder, according to a review published in Cochrane Database of Systematic Reviews.
Pregnancy inflammation linked to postpartum anxiety among those with most severe symptoms
NEW YORK — New data suggests a link between inflammation during pregnancy and postpartum anxiety among women experiencing the highest anxiety symptoms, according to a poster at the American Psychiatric Association annual meeting.
VIDEO: One dose of LSD improved generalized anxiety disorder up to 12 weeks
NEW YORK — One dose of lysergide produced clinical remission of generalized anxiety disorder as soon as 4 weeks after treatment, according to a study presented at the American Psychiatric Association annual meeting.
FDA grants breakthrough designation to MM-120 for generalized anxiety disorder
The FDA has granted breakthrough designation to MM-120 for the treatment of generalized anxiety disorder, according to a press release from MindMed.
Positive results announced in phase 2 trial of psilocybin for generalized anxiety disorder
Incannex Healthcare has announced positive topline results from its phase 2 PsiGAD1 clinical trial of psilocybin for generalized anxiety disorder, reporting statistically significant improvement in anxiety scores compared with placebo.
MindMed achieves positive topline results in phase 2b clinical trial
MindMed has announced positive topline results from its phase 2b clinical trial of MM-120 in generalized anxiety disorder, according to a company press release.
Prevalence of MDD twice that of generalized anxiety disorder among those with epilepsy
ORLANDO — Among individuals with epilepsy, the prevalence of a major depressive disorder diagnosis was almost doubled compared with generalized anxiety disorder and varied by type of antiseizure medication used, according to a poster.
MindMed secures Zydis oral tablet technology for LSD-based anxiety treatment
Mind Medicine Inc. has announced an agreement with Catalent to use its Zydis orally disintegrating tablet technology for development of a new psychedelic-based anxiety treatment, according to a company press release.
Partnership to advance development of psychedelics for depression, anxiety
A clinical-stage biopharmaceutical company and a global contract research organization have partnered to support the ongoing development of investigational, psychedelic therapeutics to treat a range of psychiatric disorders.
Phase 2 trial of therapeutic for anxiety initiated
A Southern California-based neuroscience company has announced initiation of a phase 2 clinical trial to evaluate the safety and efficacy of investigational therapeutic ENX-102 in those with generalized anxiety disorder.